<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
Oct 18, 2010
IRVINE, Calif., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink(R) System for endovascular repair of abdominal aortic an...
Sep 28, 2010
IRVINE, Calif., Sept 28, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the online publication of a long-term outcome analysis of abdominal aortic aneurysm (AAA) patients from the pivotal, multicenter, prospective clinical trials for the C...
Aug 26, 2010
IRVINE, Calif., Aug 26, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it received CE Mark approval to market its expanded offering of Powerlink(R) stent graft products and PowerFit(TM) Aortic Extensions in the European Union. The Co...
Aug 16, 2010
IRVINE, Calif., Aug 16, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has entered into a development agreement and exclusive license with Evasc Medical Systems Corp., for its balloon expandable stent technology. Evasc is a medical...
Aug 11, 2010
IRVINE, Calif., Aug 11, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's pr...
Jul 29, 2010
IRVINE, Calif., July 29, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its new PowerFit(TM) Aortic Extensions. The PowerFit extensions are designed to provide physi...
Jul 26, 2010
IRVINE, Calif., July 26, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the BMO Ca...
Jul 22, 2010
IRVINE, Calif., July 22, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "During the second quarter ...
Jul 13, 2010
IRVINE, Calif., July 13, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2010 financial results, which will take place on Thursday, July 22, 2010 after the close of the market. Endologi...
Jul 6, 2010
IRVINE, Calif., July 6, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has appointed Todd Abraham to the newly created position of Vice President of Operations. Mr. Abraham will be responsible for managing all of Endologix's day-to...
Jun 10, 2010
IRVINE, Calif., June 10, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink(R) stent graft products. The approval covers 31 new sizes ...
Jun 4, 2010
IRVINE, Calif., June 4, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica H...
Jun 1, 2010
IRVINE, Calif., June 1, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference in New York, NY. ...
May 21, 2010
IRVINE, Calif., May 21, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Thomas C. Wilder has joined the Endologix Board of Directors. Mr. Wilder was elected to the Board during the Company's 2010 Annual Meeting of Stockholders held on ...
Apr 28, 2010
IRVINE, Calif., April 28, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of consolidated results from its prospective, multicenter clinical trials of the Company's Powerlink(R) stent graft for the endovascular repair of abd...
= add release to Briefcase